Size Matters When it Comes to Drug, Biologic Fee Waivers
By Mari Serebrov
Monday, March 14, 2011
WASHINGTON One company's gain could be another's loss if the FDA raises the financial resources threshold for user fee waivers for drugs and biologics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.